1 July 2024
Scancell Holdings plc
("Scancell" or the
"Company")
Block
Listing Return and Total Voting
Rights
Change of
Name of Nominated Adviser and Joint Broker
Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer,
announces that it has allotted and issued a
further 620,000 new ordinary shares of £0.001 each ("Ordinary
Shares"), pursuant to its block listing facility, in satisfaction
of the exercise of share options granted under the Company's
existing options plan.
Following this issue, there will be
a total of 929,599,977 Ordinary Shares in issue. This figure may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure and Transparency
Rules.
Block Listing Return
The Company makes the following
notification pursuant to Schedule Six of the AIM Rules for
Companies regarding its existing block admission
arrangements:
|
Name of applicant:
|
Scancell Holdings plc
|
|
Number and class of securities
originally admitted:
|
2,880,000 ordinary shares of £0.001
each
|
|
Date of admission:
|
17 April 2023
|
|
Period of return:
|
From:
|
17 October 2023
|
To:
|
30 June 2024
|
|
Balance of unallotted securities
under scheme(s) from previous return:
|
620,000
|
|
Plus: The amount by which the block
scheme(s) has been increased since the date of the last return (if
any increase has been applied for):
|
0
|
|
Less: Number of securities
issued/allotted under scheme(s) during period (see
LR3.5.7G):
|
620,000
|
|
Equals: Balance under scheme(s) not yet
issued/allotted at end of period:
|
0
|
|
Total number
of securities in issue at the end of the
period
|
929,599,977
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Change of Name of Nominated Adviser
and Joint Broker
The Company also announces that its
Nominated Adviser and Joint Broker has changed its name to Panmure
Liberum Limited following completion of its own corporate
merger.
|
For further
information, please contact:
|
|
|
Scancell
Holdings plc
|
+44 (0) 20 3709 5700
|
|
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
Panmure Liberum
Limited (Nominated Advisor and Joint Broker)
Emma Earl, Freddy Crosslet, Will Goode, Mark Rogers
(Corporate Finance)
Rupert Dearden (Corporate Broking)
|
+44 (0) 20 7886 2500
|
|
WG Partners LLP
(Joint Broker)
|
+44 (0) 20 3705 9330
|
|
David Wilson/Claes Spang/Satheesh
Nadarajah/Erland Sternby
|
|
About
Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer and infectious disease. The Company is
building a pipeline of innovative products by utilising its four
technology platforms: Moditope®
and ImmunoBody®
for vaccines and GlyMab® and
AvidiMab® for
antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab®) or
enhances the potency of antibodies and their ability to directly
kill tumour cells
(AvidiMab®).
For further information about Scancell, please
visit: https://www.scancell.co.uk/
